+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07622342

Randomized Study to Assess SHR-2173 Injection Added to Standard Care for Generalized Myasthenia Gravis

Led by Guangdong Hengrui Pharmaceutical Co., Ltd · Updated on 2026-10-22

60

Participants Needed

2

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate SHR-2173 as an add-on therapy to standard care for people with generalized myasthenia gravis gMG. The study aims to assess the drugs efficacy, safety, pharmacokinetics, and pharmacodynamics compared to placebo. Participants have confirmed gMG and meet specific antibody and symptom criteria. Participants are assigned to one of three groups high-dose SHR-2173 injection, low-dose SHR-2173 injection, or placebo, all added to their standard care. The trial includes a 4-week screening period, followed by 24 weeks of treatment, and a 12-week safety follow-up. The study evaluates the impact of SHR-2173 on muscle strength and daily living activities related to gMG. During the study, participants will have regular assessments of their myasthenia gravis symptoms using scores like MG-ADL, QMG, and MGC, as well as quality of life and fatigue questionnaires. Safety monitoring includes tracking adverse events. The total participation lasts approximately 40 weeks, allowing researchers to understand SHR-2173s effects and safety profile in this patient population.

CONDITIONS

Brief Title

A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis

Research Team

K

Kunming Li

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here